The Oncology Institute, Inc.

NasdaqCM:TOI Stock Report

Market Cap: US$315.6m

Oncology Institute Future Growth

Future criteria checks 1/6

Oncology Institute is forecast to grow earnings and revenue by 87.3% and 15.8% per annum respectively while EPS is expected to grow by 89.4% per annum.

Key information

87.3%

Earnings growth rate

89.42%

EPS growth rate

Healthcare earnings growth13.1%
Revenue growth rate15.8%
Future return on equityn/a
Analyst coverage

Low

Last updated16 Jul 2025

Recent future growth updates

Recent updates

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company

Jul 15
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company
author-image

Value Based Care Contracts Will Unlock Future Oncology Demand

New value-based care contracts and expanded partnerships are driving sustained growth and enhancing recurring revenue in a shifting oncology market.

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb

Apr 18
A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb

Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower

Mar 04
Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company

Jan 18
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb

Jul 19
A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb

The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 05
The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

Mar 21
Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

Mar 05
Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Nov 10
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Earnings and Revenue Growth Forecasts

NasdaqCM:TOI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20276268N/A101
12/31/2026543-7N/A32
12/31/2025465-39-11-162
3/31/2025403-53-19-16N/A
12/31/2024393-53-30-27N/A
9/30/2024379-57-38-35N/A
6/30/2024361-59-48-44N/A
3/31/2024343-60-40-37N/A
12/31/2023324-68-41-36N/A
9/30/2023310-61-52-46N/A
6/30/2023293-50-64-59N/A
3/31/2023274-40-67-60N/A
12/31/20222520-67-62N/A
9/30/2022233-1-75-71N/A
6/30/2022221-2-58-53N/A
3/31/20222106-54-50N/A
12/31/2021203-11-36-33N/A
9/30/2021200-6-13-10N/A
6/30/2021195-3-12-10N/A
3/31/2021192-5-11-9N/A
12/31/2020188-14-11N/A
12/31/2019155-424N/A
12/31/2018113-2N/A6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TOI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TOI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TOI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TOI's revenue (15.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: TOI's revenue (15.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TOI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/20 00:35
End of Day Share Price 2025/07/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Oncology Institute, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan ZhiB. Riley Securities, Inc.
David LarsenBTIG
Alexander DraperGuggenheim Securities, LLC